Perspective Therapeutics reports Q1 net loss $12.3M ($0.02/sh); cash $180.6M after $177M raise

Perspective Therapeutics, Inc.

2024-Q1 EPS reported -$0.02

Net loss $12.3M for Q1 2024 vs $0.4M year ago; R&D expense rose 127% to $7.5M.
Cash, equivalents & short-term investments $180.6M at March 31 vs $9.2M at Dec 31; additional $49.5M raised via ATM in April.
Raised $177.2M gross from public/private offerings including $20.8M private placement and Lantheus investment.
Phase 1/2a for [212Pb]VMT-α-NET dosed 9 patients; combo trial with Bristol Myers' nivolumab for VMT01 in melanoma planned.
Disclosed new pre-IND asset PSV359 targeting FAP-α; IND expected late 2024; brachytherapy divested to GT Medical.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 15, 2024, Perspective Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing recent business highlights.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.